Franklin Genomic Advancements ETF (HELX) Holdings
HELX holdings summary
as of Oct 24, 2026- Holdings
- 65 positions listed
- Top 10 weight
- 48.8% of net assets
- Effective holdings
- 26 equal-weight equivalent
- Largest holding
- NTRA 10.59% Natera, Inc.
- Annual turnover
- 33.8% of the portfolio traded
All HELX holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera, Inc. | Healthcare | 10.59% | $3.6M | $56.71B | — |
| 2 | GH | Guardant Health, Inc. | Healthcare | 9.22% | $3.2M | $21.28B | — |
| 3 | KRYS | Krystal Biotech, Inc. | Healthcare | 4.81% | $1.6M | $9.37B | 39.7 |
| 4 | ADPT | Adaptive Biotechnologies Corporation | Healthcare | 4.49% | $1.5M | $3.83B | — |
| 5 | LGND | Ligand Pharmaceuticals Incorporated | Healthcare | 4.37% | $1.5M | $5.89B | 31.1 |
| 6 | TWST | Twist Bioscience Corporation | Healthcare | 3.99% | $1.4M | $8.80B | — |
| 7 | MEDP | Medpace Holdings, Inc. | Healthcare | 2.96% | $1.0M | $17.26B | 36.3 |
| 8 | BBIO | BridgeBio Pharma, Inc. | Healthcare | 2.91% | $995,684.95 | $12.98B | — |
| 9 | UTHR | United Therapeutics Corporation | Healthcare | 2.72% | $929,538.29 | $22.87B | 19.1 |
| 10 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 2.70% | $922,841.62 | $126.66B | 28.9 |
| 11 | LLY | Eli Lilly and Company | Healthcare | 2.60% | $887,444.96 | $1.12T | 42.2 |
| 12 | VYLR | Vylor Inc. | Financial Services | 2.33% | $794,477.46 | $48.17B | 103.1 |
| 13 | TVTX | Travere Therapeutics, Inc. | Healthcare | 2.31% | $788,224.96 | $4.61B | — |
| 14 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 2.21% | $756,244.96 | $81.41B | 19.6 |
| 15 | RGEN | Repligen Corporation | Healthcare | 1.99% | $679,779.97 | $11.14B | 240.3 |
| 16 | GRAL | GRAIL, Inc. | Healthcare | 1.93% | $659,245.80 | $5.26B | — |
| 17 | TEM | Tempus AI, Inc. | Healthcare | 1.93% | $658,630.80 | $11.68B | — |
| 18 | CDNA | CareDx, Inc | Healthcare | 1.93% | $658,630.80 | $3.31B | 30.8 |
| 19 | CRL | Charles River Laboratories International, Inc. | Healthcare | 1.85% | $633,313.30 | $14.46B | — |
| 20 | ARGX | Argen-X | Healthcare | 1.47% | $501,839.98 | — | — |
| 21 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 1.41% | $483,424.14 | $13.79B | 19.9 |
| 22 | JAZZ | Jazz Pharmaceuticals plc | Healthcare | 1.21% | $413,211.65 | $13.65B | 14.4 |
| 23 | IQV | IQVIA Holdings Inc. | Healthcare | 1.11% | $378,566.65 | $43.93B | 33.2 |
| 24 | TXG | 10x Genomics, Inc. | Healthcare | 1.07% | $365,378.32 | $9.10B | — |
| 25 | HNGE | Hinge Health, Inc. | Healthcare | 1.07% | $364,626.65 | $8.00B | 32.7 |
| 26 | VCYT | Veracyte, Inc. | Healthcare | 1.05% | $360,082.48 | $3.47B | 30.8 |
| 27 | BNTX | BioNTech SE | Healthcare | 1.04% | $355,811.65 | $22.03B | — |
| 28 | RPRX | Royalty Pharma plc | Healthcare | 1.03% | $353,146.65 | $35.22B | 32.4 |
| 29 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Healthcare | 1.00% | $342,759.98 | $6.13B | 79.4 |
| 30 | SRT3 | Sartorius Aktiengesellschaft | Healthcare | 0.98% | $335,004.15 | — | — |
| 31 | 207940 | Samsung Biologics Co Ltd | Healthcare | 0.98% | $333,432.48 | — | — |
| 32 | PTCT | PTC Therapeutics, Inc. | Healthcare | 0.97% | $332,851.65 | $4.94B | — |
| 33 | TMO | Thermo Fisher Scientific Inc. | Healthcare | 0.96% | $327,999.98 | $255.13B | 37.1 |
| 34 | STOK | Stoke Therapeutics, Inc. | Healthcare | 0.94% | $322,259.98 | $1.56B | — |
| 35 | RVMD | Revolution Medicines, Inc. | Healthcare | 0.92% | $313,649.98 | $38.14B | — |
| 36 | PRAX | Praxis Precision Medicines, Inc. | Healthcare | 0.86% | $295,268.32 | $6.75B | — |
| 37 | CRSP | CRISPR Therapeutics AG | Healthcare | 0.84% | $286,794.99 | $4.76B | — |
| 38 | INSM | Insmed Incorporated | Healthcare | 0.77% | $261,853.32 | $21.02B | — |
| 39 | ANAB | AnaptysBio, Inc. | Healthcare | 0.73% | $249,143.32 | $1.39B | — |
| 40 | A | Agilent Technologies, Inc. | Healthcare | 0.72% | $246,956.65 | $48.77B | 34.1 |
| 41 | CDNS | Cadence Design Systems, Inc. | Technology | 0.70% | $238,995.82 | $88.13B | 63.5 |
| 42 | TRAX | First Tracks Biotherapeutics | Healthcare | 0.69% | $237,150.82 | $1.23B | — |
| 43 | GMAB | Genmab A/S | Healthcare | 0.67% | $229,565.82 | $22.75B | 29.1 |
| 44 | BEAM | Beam Therapeutics Inc. | Healthcare | 0.63% | $215,933.32 | $2.42B | — |
| 45 | MRNA | Moderna, Inc. | Healthcare | 0.62% | $211,354.99 | $87.04B | — |
| 46 | ETON | Eton Pharmaceuticals, Inc. | Healthcare | 0.61% | $209,202.49 | $1.44B | 125.8 |
| 47 | QGEN | Qiagen N.V. | Healthcare | 0.56% | $190,547.49 | $9.53B | 23.4 |
| 48 | MANE | Veradermics, Incorporated | Healthcare | 0.52% | $178,349.99 | $4.55B | — |
| 49 | AZN | AstraZeneca PLC | Healthcare | 0.50% | $171,687.49 | — | — |
| 50 | GKOS | Glaukos Corporation | Healthcare | 0.49% | $166,391.66 | $9.72B | — |
| 51 | TGTX | TG Therapeutics, Inc. | Healthcare | 0.48% | $163,521.66 | $8.26B | 19.6 |
| 52 | AXSM | Axsome Therapeutics, Inc. | Healthcare | 0.46% | $157,064.16 | $8.23B | — |
| 53 | ROIV | Roivant Sciences Ltd. | Healthcare | 0.46% | $155,594.99 | $24.22B | — |
| 54 | ARQT | Arcutis Biotherapeutics, Inc. | Healthcare | 0.45% | $153,784.16 | $3.62B | 131.0 |
| 55 | CTVA | Corteva, Inc. | Basic Materials | 0.38% | $130,448.33 | $8.59B | 8.0 |
| 56 | MLYS | Mineralys Therapeutics, Inc. | Healthcare | 0.36% | $124,366.66 | $1.79B | — |
| 57 | COGT | Cogent Biosciences, Inc. | Healthcare | 0.35% | $118,558.33 | $5.12B | — |
| 58 | CELC | Celcuity Inc. | Healthcare | 0.32% | $109,640.83 | $2.77B | — |
| 59 | RYTM | Rhythm Pharmaceuticals, Inc. | Healthcare | 0.30% | $103,934.99 | $5.91B | — |
| 60 | ONC | BeiGene, Ltd. | Healthcare | 0.29% | $97,511.66 | $41.99B | 66.0 |
| 61 | BIO | Bio-Rad Laboratories, Inc. | Healthcare | 0.28% | $96,794.16 | $9.46B | 44.8 |
| 62 | TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | 0.27% | $90,883.33 | $3.19B | — |
| 63 | NGNE | Neurogene Inc. | Healthcare | 0.16% | $53,470.83 | $465.3M | — |
| 64 | LQDA | Liquidia Corporation | Healthcare | 0.13% | $43,630.83 | $3.07B | 24.7 |
| 65 | WGS | GeneDx Holdings Corp. | Healthcare | 0.11% | $37,993.33 | $1.90B | — |
Weights as a percentage of net assets. Value held = weight × net assets ($34.2M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
HELX sector breakdown
| Sector | Weight | Holdings | Largest |
|---|---|---|---|
| Healthcare | 96.4% | 62 | NTRA, GH, KRYS |
| Financial Services | 2.3% | 1 | VYLR |
| Technology | 0.7% | 1 | CDNS |
| Basic Materials | 0.4% | 1 | CTVA |
Sum of the weights of the holdings in each sector.
HELX top industries
HELX overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| IWM | iShares Russell 2000 ETF | 4.4% | 31 of 1,962 | 0.19% |
| VTI | Vanguard Total Stock Market ETF | 3.0% | 54 of 2,941 | 0.03% |
| SPY | SPDR S&P 500 ETF | 2.7% | 10 of 502 | 0.09% |
| QQQ | Invesco QQQ ETF | 1.7% | 4 of 101 | 0.17% |
| VXUS | Vanguard Total International Stock ETF | 0.7% | 6 of 8,035 | 0.05% |
| DIA | SPDR Dow Jones Industrial Average ETF | 0.0% | 0 of 30 | 0.16% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the HELX portfolio
Franklin Genomic Advancements ETF holds 65 positions. The ten largest make up 48.8% of the fund and the top 50 95.0%, so it behaves like a portfolio of about 26 equally weighted stocks. The biggest positions are Natera, Inc. (10.59%), Guardant Health, Inc. (9.22%), Krystal Biotech, Inc. (4.81%), Adaptive Biotechnologies Corporation (4.49%), Ligand Pharmaceuticals Incorporated (4.37%).
By sector, Healthcare is 96.4%, Financial Services is 2.3%, Technology is 0.7%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 24, 2026; positions change as the fund rebalances.
Related: HELX chart, HELX performance, HELX dividends, HELX overview.
HELX holdings FAQ
How many holdings does HELX have?
HELX holds 65 positions as of October 24, 2026.
What are the top 10 holdings of HELX?
The ten largest holdings are Natera, Inc. (10.59%), Guardant Health, Inc. (9.22%), Krystal Biotech, Inc. (4.81%), Adaptive Biotechnologies Corporation (4.49%), Ligand Pharmaceuticals Incorporated (4.37%), Twist Bioscience Corporation (3.99%), Medpace Holdings, Inc. (2.96%), BridgeBio Pharma, Inc. (2.91%), United Therapeutics Corporation (2.72%), Vertex Pharmaceuticals Incorporated (2.70%). Together they are 48.8% of the fund.
What percentage of HELX is Natera, Inc.?
Natera, Inc. is the largest holding at 10.59% of net assets, about $3.6M of the fund's $34.2M.
Which sector is the largest in HELX?
Healthcare is the largest sector at 96.4%, followed by Financial Services (2.3%) and Technology (0.7%), based on the sectors of the individual holdings.
How concentrated is HELX?
The top 10 holdings are 48.8% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) HELX behaves like a portfolio of about 26 equally weighted stocks.